After four years of negotiations, European lawmakers have agreed on a new EU Medical Devices Regulation (MDR). The MDR is the alike the US FDA’s CDRH regulations and fundamentally postulates the appropriate rules when introducing m…
According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million.??
Entering China after 2000, insulin secretagogues agent is mainly used for the treatment of type 2 diabetes. Currently, there are only 3 kinds available in the Chinese market, namely, nateglinide, repaglinide and mitiglinide. They share the same mechanism of action, that is to say, they lower blood glucose by stimulating the release of insulin from the beta cells. Compared with sulfonylurea, insulin secretagogues agent reports shorter duration of glucoselowering action and lower rate of hypoglycemia.
As an insulin secretagogues agent structured different from sulfonylurea, repaglinide is used to control postprandial hyperglycemia. Developed by Novo Nordisk A/S and BoehringerIngelheim together, it entered the United States in Apr. 1998.
As the first new prandial glucose regulator, repaglinide belongs to the class of benzoic acid derivative. Containing a chiral carbon atom, it has stereoselective activity and can be absorbed well on an empty stomach or not. As repaglinide is expelled from the body with bile after being metabolized by CYP3A4 enzyme system in the liver and only 6% of it is excreted through kidney, it is more suitable for patients with kidney disorders. Hence its advantage in the clinic. In 2000, repaglinide of Novo Nordisk A/S came to be sold in China under the name of Novonorm. According to CRI's market survey, it has few rivals and takes up a market share of about 89% for sales value while its main competitor Hanson Pharmaceutical only occupies less than 11% of the market. The sales value of repaglinide in sample hospitals was about CNY 125 million in 2014 and CAGR during the period of 20052014 reached about 22%.
The market size of repaglinide is expected to keep growing in the next few years in China.
Readers can get at least the following information through this report:
- market size of repaglinide in China
- major manufacturers of repaglinide for Chinese market and their market share
- retail price of repaglinide in Chinese market
- market outlook of repaglinide in China
The author suggests the following groups of people purchase this report:
- manufacturers of antidiabetic drugs
- investors/ research institutions interested in Chinese medicine market
- any interest in the Chinese medicine market, please contact CRI for customized survey service